• Rachel Wong, Tanvi Mehta, Bradley Very, Jing Luo, Kristian Feterik, Bradley H Crotty, Jeremy A Epstein, Michael J Fliotsos, Nitu Kashyap, Erika Smith, Fasika A Woreta, and Jeremy I Schwartz.
• Department of Biomedical Informatics, Renaissance School of Medicine at Stony Brook, Stony Brook, USA. rachel.wong@stonybrookmedicine.edu.
• J Gen Intern Med. 2023 Mar 1; 38 (4): 103810451038-1045.

AbstractThe problem of unaffordable prescription medications in the United States is complex and can result in poor patient adherence to therapy, worse clinical outcomes, and high costs to the healthcare system. While providers are aware of the financial burden of healthcare for patients, there is a lack of actionable price transparency at the point of prescribing. Real-time prescription benefit (RTPB) tools are new electronic clinical decision support tools that retrieve patient- and medication-specific out-of-pocket cost information and display it to clinicians at the point of prescribing. The rise in US healthcare costs has been a major driver for efforts to increase medication price transparency, and mandates from the Centers for Medicare & Medicaid Services for Medicare Part D sponsors to adopt RTPB tools may spur integration of such tools into electronic health records. Although multiple factors affect the implementation of RTPB tools, there is limited evidence on outcomes. Further research will be needed to understand the impact of RTPB tools on end results such as prescribing behavior, out-of-pocket medication costs for patients, and adherence to pharmacologic treatment. We review the terminology and concepts essential in understanding the landscape of RTPB tools, implementation considerations, barriers to adoption, and directions for future research that will be important to patients, prescribers, health systems, and insurers.© 2022. The Author(s), under exclusive licence to Society of General Internal Medicine.

12 keywords...

hide…